Infants Eligible for Neonatal Hypoglycemia Screening: A Systematic Review
Related Experiment Video
Updated: Jul 15, 2025

Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Michelle O'Brien1,2, Catherine Gilchrist1, Lynn Sadler3,4
1Department of Paediatrics, Child and Youth Health, Waipapa Taumata Rau - The University of Auckland, Auckland, New Zealand.
Insights
Neonatal hypoglycemia screening is recommended, but guidelines vary. A study found about one-quarter of infants met screening criteria, highlighting the need for research into which infants benefit most.
Area of Science:
- Neonatal care
- Endocrinology
- Public Health
Background:
- Neonatal hypoglycemia is common and linked to neurodevelopmental issues.
- Existing guidelines recommend screening at-risk infants, but the proportion needing screening is unclear.
Approach:
- Systematic review of 18 clinical practice guidelines for neonatal hypoglycemia.
- Retrospective cohort study of 101,372 infants using criteria from the highest-scoring guideline.
- Analysis of screening criteria variability and proportion of eligible infants over 15 years.
Key Points:
- Guideline quality and screening criteria for neonatal hypoglycemia lacked consensus.
- The highest-scoring guideline identified infants of diabetic mothers, preterm, SGA, or with extreme birth weights as eligible.
- Overall, 26.3% of infants were eligible for screening, with no significant change over 15 years.
Conclusions:
- Significant variability exists in clinical guidelines for neonatal hypoglycemia screening.
- Approximately one-quarter of infants met screening criteria, indicating a substantial need for screening.
- Further research is necessary to determine which infants benefit most from neonatal hypoglycemia screening.
Importance:
Neonatal hypoglycemia is common, occurring in up to 50% of infants at risk for hypoglycemia (infant of diabetic mother [IDM], small for gestational age [SGA], large for gestational age [LGA], and preterm) and is associated with long-term neurodevelopmental impairment. Guidelines recommend screening infants at risk of hypoglycemia. The proportion of infants who require screening for neonatal hypoglycemia is unknown.
Objective:
To determine the proportion of infants eligible for neonatal hypoglycemia screening using criteria from the highest-scoring critically appraised clinical guideline.
Design, Setting, And Participants:
This systematic review of the literature was conducted to identify clinical practice guidelines for neonatal hypoglycemia and took place at a tertiary maternity hospital in Auckland, New Zealand. Eligible guidelines were critically appraised using the Appraisal of Guidelines for Research and Evaluation II tool. Using screening criteria extracted from the highest-scoring guideline, the proportion of infants eligible for neonatal hypoglycemia screening was determined in a retrospective observational cohort study of infants born January 1, 2004, to December 31, 2018. Data were analyzed by logistic regression. Infant participants were included if gestational age was 35 weeks or more, birth weight was 2000 g or more, and they were not admitted to a neonatal intensive care unit less than 1 hour after birth. The data were analyzed from November 2022 through February 2023. A total of 101 372 infants met the inclusion criteria.
Exposure:
Risk factors for neonatal hypoglycemia.
Main Outcome:
Proportion of infants eligible for neonatal hypoglycemia screening.
Results:
The study team screened 2366 abstracts and 18 guidelines met inclusion criteria for appraisal. There was variability in the assessed quality of guidelines and a lack of consensus between screening criteria. The highest-scoring guideline defined screening criteria as: IDM, preterm (less than 37 weeks' gestation), SGA (less than 10th percentile), birth weight of less than 2500 g or more than 4500 g, LGA (more than 90th percentile), or gestational age more than 42 weeks. A total of 101 372 infants met criteria for inclusion in the cohort study; median (IQR) gestational age was 39 (38-40) weeks and 51% were male. The overall proportion of infants eligible for screening was 26.3%. There was an increase in the proportion of eligible infants from 25.6% to 28.5% over 15 years, which was not statistically significant after adjustment for maternal age, body mass index, ethnicity, and multiple pregnancy (odds ratio, 0.99; 95% CI, 0.93-1.03; change in proportion per year).
Conclusion:
A systematic review found that practice guidelines providing recommendations for clinical care of neonatal hypoglycemia were of variable quality with is a lack of consensus regarding definitions for infants at risk for hypoglycemia. In the cohort study, one-quarter of infants were eligible for hypoglycemia screening. Further research is required to identify which infants may benefit from neonatal hypoglycemia screening.
Related Concept Videos
Hypoglycemia and Glucagon
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Type 2 and Gestational

